Journal ArticleDOI
Clinical and biologic implications of recurrent genomic aberrations in myeloma
Rafael Fonseca,Emily A. Blood,Montserrat Rué,David P. Harrington,Martin M. Oken,Robert A. Kyle,Gordon W. Dewald,Brian G Van Ness,Scott Van Wier,Kimberly J. Henderson,Richard J. Bailey,Philip R. Greipp +11 more
Reads0
Chats0
TLDR
A stratification of patients into 3 distinct categories allowed for prognostication: poor prognosis group (t(4;14)(p16;q32), t(14; 16)(q32;q23), and - 17p13), intermediate prognosis (- 13q14), and good prognosis groups (all others).About:
This article is published in Blood.The article was published on 2003-06-01. It has received 619 citations till now.read more
Citations
More filters
Journal ArticleDOI
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
Shaji Kumar,Angela Dispenzieri,Martha Q. Lacy,Morie A. Gertz,Francis K. Buadi,Shivlal Pandey,Prashant Kapoor,David Dingli,Suzanne R. Hayman,Nelson Leung,John A. Lust,Arleigh McCurdy,Stephen J. Russell,Steven R. Zeldenrust,Robert A. Kyle,S V Rajkumar +15 more
TL;DR: It is demonstrated that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably, highlighting the impact of initial therapy with novel agents.
Journal ArticleDOI
The molecular classification of multiple myeloma
Fenghuang Zhan,Yongsheng Huang,Yongsheng Huang,Simona Colla,Simona Colla,James P. Stewart,James P. Stewart,Ichiro Hanamura,Ichiro Hanamura,Sushil K. Gupta,Sushil K. Gupta,Joshua Epstein,Joshua Epstein,Shmuel Yaccoby,Shmuel Yaccoby,Jeffrey R. Sawyer,Jeffrey R. Sawyer,Bart Burington,Bart Burington,Elias Anaissie,Elias Anaissie,Klaus Hollmig,Klaus Hollmig,Mauricio Pineda-Roman,Mauricio Pineda-Roman,Guido J Tricot,Guido J Tricot,Frits van Rhee,Frits van Rhee,Ronald Walker,Ronald Walker,Maurizio Zangari,Maurizio Zangari,John Crowley,John Crowley,Bart Barlogie,Bart Barlogie,John D. Shaughnessy +37 more
TL;DR: A subset of cases with a predominating myeloid gene expression signature had more favorable baseline characteristics and superior prognosis to those lacking this signature, suggesting that this signature is linked to disease progression.
Journal ArticleDOI
Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
Jonathan J Keats,Rafael Fonseca,Marta Chesi,Roelandt F.J. Schop,Angela Baker,Wee Joo Chng,Scott Van Wier,Rodger E. Tiedemann,Chang Xin Shi,Michael Sebag,Esteban Braggio,Travis J. Henry,Yuan Xiao Zhu,Homer Fogle,Tammy Price-Troska,Gregory J. Ahmann,Catherine Mancini,Leslie A. Brents,Shaji Kumar,Philip R. Greipp,Angela Dispenzieri,Barb Bryant,George Mulligan,Laurakay Bruhn,Michael T. Barrett,Riccardo Valdez,Jeff Trent,A. Keith Stewart,John D. Carpten,P. Leif Bergsagel +29 more
TL;DR: In this paper, an integrated analysis of high-density oligonucleotide array CGH and gene expression profiling data from 155 multiple myeloma samples identified a promiscuous array of abnormalities contributing to the dysregulation of NF-kappaB in approximately 20% of patients.
Journal ArticleDOI
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
Robert A. Kyle,S V Rajkumar +1 more
TL;DR: A new risk stratification model is provided to specifically define high-risk patients who may benefit from novel therapeutic strategies in multiple myeloma.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Individual Comparisons by Ranking Methods
TL;DR: The comparison of two treatments generally falls into one of the following two categories: (a) a number of replications for each of the two treatments, which are unpaired, or (b) we may have a series of paired comparisons, some of which may be positive and some negative as mentioned in this paper.
Journal ArticleDOI
Asymptotically Efficient Rank Invariant Test Procedures
Richard Peto,Julian Peto +1 more
Book
analysis of binary data
David Cox,E. J. Snell +1 more
TL;DR: Binary response variables special logistical analyses some complications some related approaches more complex responses.
Book
Modelling Survival Data in Medical Research
TL;DR: This paper discusses the design of clinical trials, use of computer software in survival analysis, and some non-parametric procedures for modelling survival data.
Related Papers (5)
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome
Hervé Avet-Loiseau,Michel Attal,Philippe Moreau,Catherine Charbonnel,Frédéric Garban,Cyrille Hulin,Serge Leyvraz,Mauricette Michallet,Ibrahim Yakoub-Agha,Laurent Garderet,Gerald Marit,Lucienne Michaux,Laurent Voillat,Marc Renaud,Bernard Grosbois,Gaelle Guillerm,Lotfi Benboubker,Mathieu Monconduit,Catherine Thieblemont,Philippe Casassus,Denis Caillot,Anne-Marie Stoppa,Jean-Jacques Sotto,Marc Wetterwald,Charles Dumontet,Jean-Gabriel Fuzibet,Isabelle Azais,Véronique Dorvaux,Marc Zandecki,Régis Bataille,Stephane Minvielle,Jean-Luc Harousseau,Thierry Facon,Claire Mathiot +33 more
Genetics and Cytogenetics of Multiple Myeloma A Workshop Report
Rafael Fonseca,Bart Barlogie,Régis Bataille,Christian Bastard,P. Leif Bergsagel,Marta Chesi,Faith E. Davies,Johannes Drach,Philip R. Greipp,Ilan R. Kirsch,W. Michael Kuehl,Jesus M. Hernandez,Stephane Minvielle,Linda M. Pilarski,John D. Shaughnessy,A. Keith Stewart,Hervé Avet-Loiseau,Hervé Avet-Loiseau +17 more
International staging system for multiple myeloma.
Philip R. Greipp,Jesús F. San Miguel,Brian G.M. Durie,John Crowley,Bart Barlogie,Joan Bladé,Mario Boccadoro,J. Anthony Child,Hervé Avet-Loiseau,Robert A. Kyle,Juan J. Lahuerta,Heinz Ludwig,Gareth J. Morgan,R. L. Powles,Kazuyuki Shimizu,Chaim Shustik,Pieter Sonneveld,Patrizia Tosi,Ingemar Turesson,Jan Westin +19 more
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy,Fenghuang Zhan,Bart Burington,Yongsheng Huang,Simona Colla,Ichiro Hanamura,James P. Stewart,Bob Kordsmeier,Christopher Randolph,David R. Williams,Yan Xiao,Hongwei Xu,Joshua Epstein,Elias Anaissie,Somashekar G. Krishna,Michele Cottler-Fox,Klaus Hollmig,Abid Mohiuddin,Mauricio Pineda-Roman,Guido Tricot,Frits van Rhee,Jeffrey R. Sawyer,Yazan Alsayed,Ronald C. Walker,Maurizio Zangari,John Crowley,Bart Barlogie +26 more